Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder

International Journal of Biological Markers

Volumn 24, Issue 1, 2009, Pages 17-21

  Boulalas, Ioannis ^a   Zaravinos, Apostolos ^b   Delakas, Demetrios ^a   Spandidos, Demetrios A ^b  

^a IASO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

BRAF mutations; Transitional cell carcinoma

Indexed keywords

B RAF KINASE; ONCOPROTEIN; SERINE; THREONINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE ACTIVATION; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; INTRON; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; TRANSITIONAL CELL CARCINOMA;

EID: 67649933709     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2009.4457     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2008; 58: 71-96.
2. Spiess PE, Czerniak B. Dual-track pathway of bladder carcinogenesis: practical implications. Arch Pathol Lab Med 2006; 130: 844-52.
3. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-2.
4. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
5. Helmke BM, Mollenhauer J, Herold-Mende C, et al. BRAF mutations distinguish anorectal from cutaneous melanoma at the molecular level. Gastroenterology 2004; 127: 1815-20.
6. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33: 19-20.
7. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
8. Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 2004; 46: 170-6.
9. Greene FL, Sobin LH. The staging of cancer: a retrospective and prospective appraisal. CA Cancer J Clin 2008; 58: 180-90.
10. Kanellou P, Zaravinos A, Zioga M, et al. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis. Cancer Lett 2008; 264: 145-61.
11. Zaravinos A, Bizakis J, Spandidos DA. RKIP and BRAF aberrations in human nasal polyps and the adjacent turbinate mucosae. Cancer Lett 2008; 264: 288-98.
12. O'Neill E, Kolch W. Conferring specificity on the ubiquitous Raf/MEK signalling pathway. Br J Cancer 2004; 90: 283-8.
13. Duesbery NS, Webb CP, Vande Woude GF. MEK wars, a new front in the battle against cancer. Nat Med 1999; 5: 736-7.
14. Avruch J, Khokhlatchev A, Kyriakis JM, et al. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 2001; 56: 127-55.
15. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-7.
16. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002; 62: 7001-3.
17. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62: 6997-7000.
18. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002; 62: 6451-5.
19. Stoehr R, Brinkmann A, Filbeck T, et al. No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract. Oncol Rep 2004; 11: 137-41.
20. Cho NY, Choi M, Kim BH, Cho YM, Moon KC, Kang GH. BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer 2006; 119: 1858-62.
21. Burger M, Denzinger S, Hammerschmied C, et al. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations. Eur Urol 2006; 50: 1102-9.
22. Sommerer F, Hengge UR, Markwarth AR, et al. Mutations of BRAF and RAS are rare events in germ cell tumours. Int J Cancer 2005; 113: 329-35.
23. Nagy A, Balint I, Kovacs G. Frequent allelic changes at chromosome 7q34 but lack of mutation of the BRAF in papillary renal cell tumors. Int J Cancer 2003; 106: 980-1.
24. McIntyre A, Summersgill B, Spendlove HE, Huddart R, Houlston R, Shipley J. Activating mutations and/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors. Neoplasia 2005; 7: 1047-52.
25. Ueda M, Toji E, Nunobiki O, et al. Mutational analysis of the BRAF gene in human tumor cells. Hum Cell 2008; 21: 13-7.
26. de Jong J, Stoop H, Gillis AJ, et al. Further characterization of the first seminoma cell line TCam-2. Genes Chromosomes Cancer 2008; 47: 185-96.
27. Cerniak B, Cohen GL, Etkind P, et al. Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol 1992; 23: 1199-204.
28. Saito S, Hata M, Fukuyama R, et al. Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. Int J Urol 1997; 4: 178-85.
29. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003; 22: 4578-80.
30. Boulalas I, Zaravinos A, Karyotis I, Delakas D, Spandidos DA. Activation of the RAS family genes in urothelial carcinoma. J Urol 2009 (in press).
31. Basu A, Sivaprasad U. Protein kinase Cepsilon makes the life and death decision. Cell Signal 2007; 19: 1633-42.
32. Perletti GP, Concari P, Brusaferri S, Marras E, Piccinini F, Tashjian AH Jr. Protein kinase Cepsilon is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway. Oncogene 1998; 16: 3345-8.